Clinical and laboratory parameters associated with outcomes in patients with metastatic renal cell carcinoma treated with modified vaccinia Ankara delivering tumor antigen 5T4.

Abstract

e13132 Background: Two separate studies have been conducted to study the efficacy of modified vaccinia Ankara delivering tumor antigen 5T4 (TroVax) alone, in combination with either interleukin-2 or interferon-α totaling 53 patients (Clin Cancer Res 2008; 14[22], J Immunother 2009; 32[7]). We will review the overall survival of this patient population of <12 months, >12 months and >24 months and provide correlation with their baseline clinical and laboratory parameters. Methods: We have reviewed baseline data of 53 patients. The entire baseline laboratory parameters were assessed. Clinical data such as pathology, diagnosed to initial therapy with TroVax, time of metastases development, the number of metastatic lesions and performance status. Both univariate and multivariate analyses were conducted. Results: Analysis of the data revealed the diagnosed time to start interval of therapy, metastasis to interval of receiving TroVax, the number of metastatic lesions, decreased leucocyte count, decreased platelet count, increased hemoglobin, decreased neutrophils, increased absolute lymphocyte, decreased corrected calcium, decreased lactate dehydrogenase, decreased albumin and decreased alkaline phosphatase correlated to overall survival. Conclusions: Results identify a specific subset of metastatic renal cell carcinoma patients with a favorable outcome based on clinical and laboratory parameters. These results can be applied as inclusion/exclusion criteria for prospective TroVax studies in addition to other cancer vaccine clinical trials. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Oxford BioMedica Oxford BioMedica